Lung Cancer News

SAN FRANCISCO — The newly reignited Cancer Moonshot is centered on the goal to reduce cancer deaths by 50% over the next 25 years.

Treatment with neoadjuvant nivolumab led to higher 5-year survival rates compared with historical data among patients with resectable non-small cell lung cancer, according to study results published in Clinical Cancer Research.

New 3D imaging technology developed at University of Michigan enables real-time measurement of radiation treatment, enhancing precision and potentially minimizing off-target effects.

Clinical trials performed within the NCI’s National Clinical Trials Network during the past 40 years prolonged the lives of patients with cancer by at least 14.2 million life-years, according to a study in Journal of Clinical Oncology.

In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more.

Among patients with solid tumors, septic shock was associated with a 69.4% 28-day mortality rate, according to a study published in CHEST.

Radiation therapy is the most common treatment for lung cancer, the most frequently diagnosed type of cancer worldwide.

Patients who received sublobar resection for early-stage non-small cell lung cancer had similar 5-year DFS rates compared with those who underwent lobectomy, according to results of a randomized phase 3 study.

Adherence to intraoperative quality metrics may increase OS and recurrence-free survival after curative-intent resection of early-stage non-small cell lung cancer, according to results of a study published in JAMA Surgery.

High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.